Bergström, S., Danielsson, H., and Samuelsson, B. 1994. The enzymatic formation of prostaglandin E2 from arachidonic acid. Prostaglandins and related factors 32. Biochim. Biophys. Acta. 90:207-210.
Samuelsson, B., Dahlén, S.E., Lindgren, J.Å., Rouzer, C.A., and Serhan, C.N. 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237:1171-1176.
Picot, D., Loll, P.J., and Garavito, R.M. 1994. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 367:243-249.
Kurumbail, R.G., et al. 1996. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384:644-648.
Dennis, E.A. 2000. Phospholipase A2 in eicosanoid generation. Am. J. Respir. Crit. Care Med. 161:S32-S35.
Van Dorp, D.A., Beerthuis, R.K., Nugteren, D., and Vonkeman, H. 1994. The biosynthesis of prostaglandins. Biochim. Biophys. Acta. 90:204-207.
Vane, J.R., Bakhle, Y.S., and Botting, R.M. 1998. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:97-120.
O'Banion, M.K., Winn, V.D., and Young, D.A. 1992. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA. 89:4888-4892.
Simmons, D.L., Botting, R.M., Robertson, P.M., Madsen, M.L., and Vane, J.R. 1999. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc. Natl. Acad. Sci. USA. 96:3275-3280.
Needleman, P., and Isakson, P.C. 1997. The discovery and function of COX-2. J. Rheumatol. 24(Suppl. 49):6-8.
Groopman, J. 1998 June 15. Superaspirin. The New Yorker. 32-35.
Hamberg, M. 1968. On the absolute configuration of 19-hydroxy-prostaglandin B1. Eur. J. Biochem. 6:147-150.
Newhall, E.P., and Winikoff, B. 2000. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am. J. Obstet. Gynecol. 183(Suppl. 2):S44-S53.
Kelly, R.W. 1997. Prostaglandins in primate semen: biasing the immune system to benefit spermatozoa and virus? Prostaglandins Leukot. Essent. Fatty Acids. 57:113-118.
Kelly, R.W., and Critchley, H.O. 1997. Immunomodulation by human seminal plasma: a benefit for spermatozoon and pathogen? Hum. Reprod. 12:2200-2207.
Denison, F.C., Grant, V.E., Calder, A.A., and Kelly, R.W. 1999. Seminal plasma components stimulate interleukin-8 and interleukin-10 release. Mol. Hum. Reprod. 5:220-226.
Kelly, R.W., et al. 1976. 19-Hydroxyprostaglandin E1 as a major component of the semen of primates. Nature. 260:544-545.
Cooper, I., and Kelly, R.W. 1975. The measurement of E and 19-hydroxy E prostaglandins in human seminal plasma. Prostaglandins. 10:507-514.
Oliw, E.H., Kinn, A.C., and Kvist, U. 1988. Biochemical characterization of prostaglandin 19-hydroxylase of seminal vesicles. J. Biol. Chem. 263:7222-7227.
Christmas, P., Ursino, S.R., Fox, J.W., and Soberman, R.J. 1999. Expression of the CYP4F3 gene. tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega- hydroxylase. J. Biol. Chem. 274:21191-21199.
Bylund, J., Finnstrom, N., and Oliw, E.H. 1999. Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles. Biochem. Biophys. Res. Commun. 261:169-174.
Hecker, M., and Ullrich, V. 1989. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J. Biol. Chem. 264:141-150.
Smith, W.L., Garavito, R.M., and DeWitt, D.L. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271:33157-33160.
Murakami, M., et al. 2000. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275:32783-32792.
von Wachenfeldt, C., and Johnson, E.F. 1995. Structure of eukaryotic cytochrome P450 enzymes. In Cytochrome P450: structure, mechanism and biochemistry. P.R. Ortiz de Montellano, editor. Plenum Press. New York, New York, USA. 182-223.
Fiore, S., and Serhan, C.N. 1989. Phospholipid bilayers enhance the stability of leukotriene A4 and epoxytetraenes: stabilization of eicosanoids by liposomes. Biochem. Biophys. Res. Commun. 159:477-481.
Bylund, J., Ericsson, J., and Oliw, E.H. 1998. Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. Anal. Biochem. 265:55-68.
Draper, A.J., and Hammock, B.D. 2000. Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase. Arch. Biochem. Biophys. 376:199-205.
Imig, J.D. 1999. Epoxyeicosatrienoic acids. Biosynthesis, regulation, and actions. Methods Mol. Biol. 120:173-192.
Hayakawa, M., et al. 1990. Proposal of leukotoxin, 9,10-epoxy-12-octadecenoate, as a burn toxin. Biochem. Int. 21:573-579.
Hu, J.N., et al. 1988. Neutrophil-derived epoxide, 9,10-epoxy-12-octadecenoate, induces pulmonary edema. Lung. 166:327-337.
Sugiyama, S., et al. 1988. The role of leukotoxin (9,10-epoxy-12-octadecenoate) in the genesis of coagulation abnormalities. Life Sci. 43:221-227.
Oliw, E.H., and Benthin, G. 1985. On the metabolism of epoxyeicosatrienoic acids by ram seminal vesicles: isolation of 5(6)epoxy-prostaglandin F1 alpha. Biochem. Biophys. Res. Commun. 126:1090-1096.
Fulton, D., Balazy, M., McGiff, J.C., and Quilley, J. 1996. Possible contribution of platelet cyclooxygenase to the renal vascular action of 5,6-epoxyeicosatrienoic acid. J. Pharmacol. Exp. Ther. 277:1195-1199.
Leffler, C.W., and Fedinec, A.L. 1997. Newborn piglet cerebral microvascular responses to epoxyeicosatrienoic acids. Am. J. Physiol. 273:H333-H338.
Stephenson, A.H., Sprague, R.S., and Lonigro, A.J. 1998. 5,6-Epoxyeicosatrienoic acid reduces increases in pulmonary vascular resistance in the dog. Am. J. Physiol. 275:H100-H109.
Han, H.J., Park, S.H., Koh, H.J., and Taub, M. 2000. Mechanism of regulation of Na+ transport by angiotensin II in primary renal cells. Kidney Int. 57:2457-2467.
Weissmann, G. 1991. Aspirin. Sci. Am. 264:84-90.
Marcus, A.J. 1995. Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333:656-658.
Levy, G.N. 1997. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 11:234-247.
Clària, J., Lee, M.H., and Serhan, C.N. 1996. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol. Med. 2:583-596.
Brezinski, M.E., and Serhan, C.N. 1990. Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc. Natl. Acad. Sci. USA. 87:6248-6252.
Stenke, L., Reizenstein, P., and Lindgren, J.A. 1994. Leukotrienes and lipoxins: new potential performers in the regulation of human myelopoiesis. Leuk. Res. 18:727-732.
Gillmor, S.A., Villasenor, A., Fletterick, R., Sigal, E., and Browner, M.F. 1997. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat. Struct. Biol. 4:1003-1009.
Serhan, C.N., and Samuelsson, B. 1988. Lipoxins: a new series of eicosanoids (biosynthesis, stereochemistry, and biological activities). Adv. Exp. Med. Biol. 229:1-14.
Romano, M., et al. 1993. Lipoxin synthase activity of human platelet 12-lipoxygenase. Biochem. J.296:127-133.
Chavis, C., Vachier, I., Chanez, P., Bousquet, J., and Godard, P. 1996. 5(S),15(S)-Dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J. Exp. Med. 183:1633-1643.
Godson, C., and Brady, H.R. 2000. Lipoxins: novel anti-inflammatory therapeutics? Curr. Opin. Investig. Drugs. 1:380-385.
Thomas, E., Leroux, J.L., Blotman, F., and Chavis, C. 1995. Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm. Res. 44:121-124.
Soyombo, O., Spur, B.W., and Lee, T.H. 1994. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Allergy. 49:230-234.
Colgan, S.P., Serhan, C.N., Parkos, C.A., Delp-Archer, C., and Madara, J.L. 1993. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 92:75-82.
Maddox, J.F., and Serhan, C.N. 1996. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183:137-146.
Serhan, C.N. 1994. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta.1212:1-25.
Lands, W.E.M. 1987. Short course on polyunsaturated fatty acids and eicosanoids. Proceedings of the American Oil Chemists' Society. Champaign, Illinois, USA.
Iigo, M., et al. 1997. Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Br. J. Cancer. 75:650-655.
Culp, B.R., Titus, B.G., and Lands, W.E.M. 1979. Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med. 3:269-278.
Giovannucci, E., et al. 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:609-614.
Steinbach, G., et al. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:1946-1952.
McGeer, P.L., Schulzer, M., and McGeer, E.G. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:425-432.
McGeer, P.L. 2000. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging. 17:1-11.
Lee, T.H., et al. 1984. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J. Biol. Chem. 259:2383-2389.
Cronstein, B.N., Kimmel, S.C., Levin, R.I., Martiniuk, F., and Weissmann, G. 1992. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA. 89:9991-9995.
Gilroy, D.W., et al. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:698-701.
Lusis, A.J. 2000. Atherosclerosis. Nature. 407:233-241.
Winslow, R. 1999 October 7. Heart-disease sleuths identify prime suspect: inflammation of artery. The Wall Street Journal.
Venturini, C.M., Isakson, P., and Needleman, P. 1998. Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms. Curr. Opin. Nephrol. Hypertens. 7:79-82.
Herschman, H.R., Xie, W., and Reddy, S. 1995. Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Bioessays. 17:1031-1037.
Chiang, N., Fierro, I.M., Gronert, K., and Serhan, C.N. 2000. Activation of lipoxin A4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J. Exp. Med. 191:1197-1207.
Takano, T., Clish, C.B., Gronert, K., Petasis, N., and Serhan, C.N. 1998. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 101:819-826.
Badr, K.F., DeBoer, D.K., Schwartzberg, M., and Serhan, C.N. 1989. Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc. Natl. Acad. Sci. USA. 86:3438-3442.
Chiang, N., et al. 1999. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104:309-316.
Hachicha, M., Pouliot, M., Petasis, N.A., and Serhan, C.N. 1999. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189:1923-1929.
Bandeira-Melo, C., et al. 2000. Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 164:1029-1036.
Serhan, C.N., Fierro, I.M., Chiang, N., and Pouliot, M. 2001. Nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4. J. Immunol. 166:3650-3654.
Fierro, I.M., and Serhan, C.N. 2001. A novel inhibitor of angiogenesis: aspirin-triggered 15R lipoxin A4. FASEB J. In press.